FDA Commissioner appointment by July 2026 sparks biotech stock rally

A new FDA commissioner appointed by mid-2026 will likely accelerate drug approval timelines, boosting biotech sector valuations. The current leadership uncertainty has suppressed investor confidence in the sector.

Implied probability (Yes)

70%